跳至主要内容
临床试验/NCT05518422
NCT05518422撤回早期 1 期

Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity

University of Missouri-Columbia0 个研究点开始时间: 2024年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
撤回
主要终点
Amount of muscle sympathetic nerve activity (MSNA)

研究概览

简要总结

The aim of this project is to determine role for ET-1 in individuals with obesity.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 18-55 years of age
  • Obese (BMI ≥30 kg/m2)

排除标准

  • Female sex
  • Current smoking/Nicotine use
  • Nerve/neurologic disease
  • Cardiovascular, hepatic, renal, respiratory disease
  • Blood pressure ≥140/90 mmHg
  • Vigorous exercise >3 times/week
  • Communication barriers
  • taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic

研究组 & 干预措施

Oral Bosentan

Experimental

干预措施: Hyperinsulinemic, euglycemic infusion (Drug)

结局指标

主要结局

Amount of muscle sympathetic nerve activity (MSNA)

时间窗: Change from baseline at minute 60

MSNA burst incidence (bursts/100 heart beats)

Amount of leg blood flow

时间窗: Change from baseline at minute 60

Measured with Doppler ultrasound (mL/min)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jacqueline K Limberg, PhD

Assistant Professor

University of Missouri-Columbia

相似试验